2001 Volume 16 Issue 2 Pages 75-91
Clinical application of pharmacokinetics/pharmacodynamics (PK/PD) from animal to human, and from normal to disease states was examined. First, we tried to elucidate the factors affecting the hepatic transport of sulfobromophthalein and indocyanine green in chronically intoxicated rats and dogs. Also, we examined the clinical implication of hepatic clearance of indocyanine green, chenodeoxicholi cacid, antipyrine, and galactose in patients with chronic liver diseases. Second, we examined the PK/PD study on β-blockers in order to establish the rational usage in patients. Third, we examined the drug interaction between new quinolones and non-steroidal antinframatic agents, and further, studied electrocardiographically on the adverse effect, QT prolongation in non-arrhythmic agents, terfenadine, ebastine and epinastine. Fourth, the metabolic inhibition of midazolam by itraconazole or ketoconazole was examined in order to evaluate the degree of drug-drug interaction concerning metabolic inhibition in the liver quantitatively, and we succeeded the prediction of increasing ratio in AUC of midazolam in concomitant administration of itraconazole or ketoconazole. Finally, we applied above outcomes to clinical practise using various approaches.
